← Back to Clinical Trials
Recruiting NCT04805437

NCT04805437 Brace Treatment for Idiopathic Scoliosis; PReventing Idiopathic SCOliosis PROgression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04805437
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Idiopathic Scoliosis
Study Type INTERVENTIONAL
Enrollment 170 participants
Start Date 2021-04-30
Primary Completion 2027-09

Eligibility & Interventions

Sex All sexes
Min Age 9 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
3D TLSOStandard TLSO

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 170 participants in total. It began in 2021-04-30 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Idiopathic scoliosis is the most common spinal deformity in children and adolescents with an estimated prevalence of 3%. About one tenth of the children with scoliosis develop a deformity that requires treatment with brace or surgery with the current treatment protocol. When brace treatment for scoliosis is indicated, standard treatment consists of bracing 20 hours or more per day. Outcomes of brace treatment depend to a large extent on wearing time and since many adolescents feel uncomfortable in the brace, it is of importance to combine efficacy and comfortability of the brace.

Eligibility Criteria

Inclusion Criteria: * Cobb 25-40 degrees * Skeletally immature, Sanders score of 6 or less and Risser 2 or less. * Menarche status maximum one year in females * Aged 9-17 years * No previous brace treatment or surgery for scoliosis * Apex of the primary curve at T7 or caudal Exclusion Criteria: * Non-idiopathic scoliosis (i.e. neuromuscular, syndromic or congenital scoliosis) * Previous spine surgery

Contact & Investigator

Central Contact

Elias Diarbakerli, PT, PhD

✉ elias.diarbakerli@sll.se

📞 +460851770000

Principal Investigator

Elias Diarbakerli, PT, PhD

PRINCIPAL INVESTIGATOR

Karolinska Institutet

Frequently Asked Questions

Who can join the NCT04805437 clinical trial?

This trial is open to participants of all sexes, aged 9 Years or older, up to 17 Years, studying Idiopathic Scoliosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04805437 currently recruiting?

Yes, NCT04805437 is actively recruiting participants. Contact the research team at elias.diarbakerli@sll.se for enrollment information.

Where is the NCT04805437 trial being conducted?

This trial is being conducted at Linköping, Sweden, Stockholm, Sweden.

Who is sponsoring the NCT04805437 clinical trial?

NCT04805437 is sponsored by Karolinska Institutet. The principal investigator is Elias Diarbakerli, PT, PhD at Karolinska Institutet. The trial plans to enroll 170 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology